KMT2A and leukemia: Intriguingly, despite the identical nature of the leukemic driver in these 2 AMLs, the Evi1high disease was found to be inherently more resistant to chemotherapy and demonstrated lower levels of apoptotic priming, which could be ascribed to retaining high expression levels of Evi1 after the transformation process.68 It remains to be investigated whether this capturing of the EVI1high epigenetic state present in HSCs can also be achieved in non-MLL-AF9 leukemias.